skip to main content
US FlagAn official website of the United States government
dot gov icon
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
https lock icon
Secure .gov websites use HTTPS
A lock ( lock ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.


Search for: All records

Creators/Authors contains: "Jones, Jesse G"

Note: When clicking on a Digital Object Identifier (DOI) number, you will be taken to an external site maintained by the publisher. Some full text articles may not yet be available without a charge during the embargo (administrative interval).
What is a DOI Number?

Some links on this page may take you to non-federal websites. Their policies may differ from this site.

  1. Across species, Epidermal Growth Factor (EGF) family ligands and their receptors participate in developmental and physiological cell-cell signaling events. C. elegans possesses a single EGF receptor, LET-23/EGFR, and two characterized EGF ligands. LIN-3/EGF is well-known for its role in vulval induction, and SISS-1/EGF mediates stress-induced sleep. The C. elegans genome harbors another predicted EGF family member, igeg-2, which has not been characterized. To determine if IGEG-2 is a functional EGFR ligand, we examined whether it can activate known LET-23-dependent processes. We found that ubiquitous overexpression of IGEG-2 promotes both vulval induction and sleep, indicating that it is a functional EGF family ligand. The endogenous role of IGEG-2 remains unknown. 
    more » « less
    Free, publicly-accessible full text available September 15, 2026
  2. The anticancer drug Gefitinib is a tyrosine kinase inhibitor with selectivity for the Epidermal Growth Factor Receptor (EGFR/ErbB1). As the C. elegans EGF receptor LET-23 shares notable structural homology over its kinase domain with human EGFR, we wished to examine whether Gefitinib treatment can interfere with LET-23-dependent processes. We show that Gefitinib disrupts C. elegans stress-induced sleep (SIS) but does not impact EGF overexpression-induced sleep nor vulva induction. These findings indicate that Gefitinib does not interfere with LET-23 signaling and impairs SIS through an off-target mechanism. 
    more » « less